Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00998933 · ClinicalTrials.gov registry record · Phase 1
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
A Phase 1 study of Hypogonadism, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00998933: Completed Phase 1 study of Hypogonadism, sponsored by Solvay Pharmaceuticals.
NCT00998933 is a Phase 1 study of Hypogonadism that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 24 participants, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00998933, a Phase 1 study of Hypogonadism, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To further characterize the transfer potential of marketed testosterone gel and new 1.62% formulation.
Conditions Studied
Interventions
- DRUG Testosterone gel 1.62%
Study Locations (1)
Florida
- Site 1 - Miami Gardens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
What the finished NCT00998933 record still lists
NCT00998933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 119-participant average among 21 other Hypogonadism trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Testosterone gel 1.62% is the first listed.
NCT00998933 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00998933 about?
NCT00998933 is a clinical study titled "Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure". To further characterize the transfer potential of marketed testosterone gel and new 1.62% formulation.
What is the current status of trial NCT00998933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-10. Estimated completion is 2009-10.
What conditions does trial NCT00998933 study?
This clinical trial studies the following conditions: Hypogonadism.
What interventions are being tested in trial NCT00998933?
The interventions under investigation include: Testosterone gel 1.62% (DRUG).
Who is sponsoring clinical trial NCT00998933?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00998933 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00998933's enrollment target sits among peer trials
24 18th of 21 higher than 3 of 21 other Hypogonadism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypogonadism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
ACTIVE NOT RECRUITING · Phase 1
-
ORAL T-6: Oral Androgens in Man-6
COMPLETED · Phase 1
-
Observation of Environment and Reproductive-Endocrine Effects
RECRUITING
-
Adaptions and Resiliency to Multi-Stressor OpeRations
RECRUITING · Phase 4
-
Inherited Reproductive Disorders
RECRUITING
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia